About ABUS

Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ABUS is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
IBB iShares Nasdaq Biotechnology Index Fund 7.3 B 7.34933E+09 222 222 0.02% 0.0002 1.2 M 1171210
IWC iShares Microcap ETF 847.3 M 8.47282E+08 1,434 1434 0.02% 0.0002 185 K 185371
IWM iShares Russell 2000 ETF 40.5 B 4.05202E+10 1,989 1989 0.0% 0 1.5 M 1490090
IWN iShares Russell 2000 Value ETF 8.6 B 8.58367E+09 1,355 1355 0.01% 0.0001 485 K 484627
IWO iShares Russell 2000 Growth ETF 8.8 B 8.79796E+09 1,232 1232 0.0% 0 167 K 167261
IWV iShares Russell 3000 ETF 9.1 B 9.10141E+09 2,929 2929 0.0% 0 27 K 27038
BIB ProShares Ultra Nasdaq Biotechnology 223.8 M 2.2382E+08 239 239 0.01% 6.76465E-05 32 K 31706
UBIO Proshares UltraPro Nasdaq Biotechnology 28.3 M 2.82606E+07 228 228 0.0% 4.46841E-05 4 K 3930
URTY ProShares UltraPro Russell2000 85.2 M 8.5176E+07 2,005 2005 0.0% 9.07416E-06 2 K 2478
UWM ProShares Ultra Russell2000 181.5 M 1.8146E+08 2,006 2006 0.0% 1.24761E-05 5 K 5066